title: Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
abstract: To evaluate the activity of gemcitabine and docetaxel in patients with recurrent ovarian cancer.
  
  
  METHODS
  Patients with platinum-resistant disease and prior treatment with paclitaxel received treatment with docetaxel on day 1 and gemcitabine on days 1 and 8, repeated every three weeks.
  
  
  RESULTS
  Twenty patients, with a platinum-free interval of three months, were enrolled. Overall response rate was 25%. Treatment was associated with significant myelosuppression.
  
  
  CONCLUSIONS
  In chemotherapy-resistant patients, this regimen exhibited encouraging activity. Excessive myelosuppression led to early closure. This was prevented by administering docetaxel on day 8 (instead of day 1) and prophylactic use of G-CSF.
authors.affiliation: Kenneth Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. aagarcia@usc.edu
authors.forename: Agustin A
authors.initials: AA
authors.lastname: Garcia
authors.forename: Anne
authors.initials: A
authors.lastname: Yessaian
authors.forename: Huyen
authors.initials: H
authors.lastname: Pham
authors.forename: Grace
authors.initials: G
authors.lastname: Facio
authors.forename: Laila
authors.initials: L
authors.lastname: Muderspach
authors.forename: Lynda
authors.initials: L
authors.lastname: Roman
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine